Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXLNASDAQ:FENCNASDAQ:IMTXNASDAQ:LENZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$7.78+3.3%$8.85$3.51▼$14.44$664.19M0.821.22 million shs1.03 million shsFENCFennec Pharmaceuticals$8.29+1.5%$5.97$3.96▼$8.33$228.96M0.3297,320 shs191,357 shsIMTXImmatics$5.12-5.2%$4.51$3.30▼$13.77$622.34M0.87659,483 shs816,766 shsLENZLENZ Therapeutics$28.16-2.0%$25.23$14.42▼$38.93$792.59M0.41185,703 shs130,563 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences-10.78%-7.27%-15.87%-13.50%+69.98%FENCFennec Pharmaceuticals+6.80%+26.08%+60.83%+23.04%+11.76%IMTXImmatics+2.08%+24.42%+26.76%+13.21%-50.64%LENZLENZ Therapeutics+0.98%-0.79%+20.61%+15.66%+54.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVXLAnavex Life Sciences3.7742 of 5 stars3.71.00.04.72.60.80.6FENCFennec Pharmaceuticals2.315 of 5 stars3.60.00.00.03.93.30.0IMTXImmatics2.8315 of 5 stars3.64.00.00.03.61.70.0LENZLENZ Therapeutics1.887 of 5 stars3.60.00.00.03.32.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.33Buy$44.00465.55% UpsideFENCFennec Pharmaceuticals 3.25Buy$13.0056.82% UpsideIMTXImmatics 3.25Buy$17.00232.03% UpsideLENZLENZ Therapeutics 3.17Buy$46.6065.48% UpsideCurrent Analyst Ratings BreakdownLatest FENC, LENZ, AVXL, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.005/14/2025FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.005/8/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/16/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/14/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.004/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/7/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/1/2025IMTXImmaticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/31/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/20/2025LENZLENZ TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$44.00 ➝ $47.003/18/2025LENZLENZ TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/AFENCFennec Pharmaceuticals$47.54M4.82N/AN/A($0.43) per share-19.28IMTXImmatics$144.15M4.32N/AN/A$2.88 per share1.78LENZLENZ TherapeuticsN/AN/AN/AN/A$22.06 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-37.50%-34.08%8/5/2025 (Estimated)FENCFennec Pharmaceuticals-$16.05M-$0.51N/AN/AN/A-2.30%-53.38%-2.08%N/AIMTXImmatics-$104.98M-$0.17N/AN/AN/A-47.94%-15.90%-9.38%N/ALENZLENZ Therapeutics-$124.65M-$1.77N/AN/AN/AN/A-58.48%-55.50%N/ALatest FENC, LENZ, AVXL, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/13/2025Q1 2025FENCFennec Pharmaceuticals-$0.12-$0.04+$0.08-$0.04$8.18 million$8.51 million5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/A3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 million3/19/2025Q4 2024LENZLENZ Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A9.459.45FENCFennec PharmaceuticalsN/A7.807.64IMTXImmaticsN/A3.983.98LENZLENZ TherapeuticsN/A28.6328.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%FENCFennec Pharmaceuticals55.51%IMTXImmatics64.41%LENZLENZ Therapeutics54.32%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%FENCFennec Pharmaceuticals11.76%IMTXImmatics3.30%LENZLENZ Therapeutics38.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.37 million75.71 millionOptionableFENCFennec PharmaceuticalsN/A27.62 million24.54 millionOptionableIMTXImmatics260121.55 million115.42 millionOptionableLENZLENZ Therapeutics11028.15 million16.94 millionN/AFENC, LENZ, AVXL, and IMTX HeadlinesRecent News About These CompaniesPoint72 Asset Management L.P. Reduces Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)May 19 at 5:53 AM | marketbeat.comParadigm Biocapital Advisors LP Purchases New Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)May 16, 2025 | marketbeat.comGranahan Investment Management LLC Buys Shares of 51,842 LENZ Therapeutics, Inc. (NASDAQ:LENZ)May 13, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Acquires 36,582 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)May 13, 2025 | marketbeat.comLeerink Partnrs Analysts Raise Earnings Estimates for LENZMay 13, 2025 | marketbeat.comHC Wainwright Issues Negative Estimate for LENZ EarningsMay 13, 2025 | marketbeat.comQ2 EPS Forecast for LENZ Therapeutics Raised by AnalystMay 13, 2025 | marketbeat.comQ2 EPS Estimate for LENZ Therapeutics Boosted by AnalystMay 13, 2025 | americanbankingnews.comLENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatmentMay 13, 2025 | msn.comLENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comHC Wainwright Reiterates "Buy" Rating for LENZ Therapeutics (NASDAQ:LENZ)May 10, 2025 | marketbeat.comEarnings call transcript: LENZ Therapeutics’ Q1 2025 results show innovation driveMay 9, 2025 | uk.investing.comLENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast AsiaMay 9, 2025 | globenewswire.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Rating of "Buy" by BrokeragesMay 9, 2025 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Bought by Alyeska Investment Group L.P.May 8, 2025 | marketbeat.comBarclays PLC Increases Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)May 8, 2025 | marketbeat.comLENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsMay 7, 2025 | globenewswire.comLENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care ConferenceMay 6, 2025 | globenewswire.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Purchased by Price T Rowe Associates Inc. MDMay 4, 2025 | marketbeat.comRenaissance Technologies LLC Sells 23,900 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)May 4, 2025 | marketbeat.comSamsara BioCapital LLC Lowers Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)May 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFENC, LENZ, AVXL, and IMTX Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$7.78 +0.25 (+3.32%) Closing price 04:00 PM EasternExtended Trading$7.56 -0.22 (-2.83%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Fennec Pharmaceuticals NASDAQ:FENC$8.29 +0.12 (+1.47%) Closing price 04:00 PM EasternExtended Trading$8.27 -0.02 (-0.24%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Immatics NASDAQ:IMTX$5.12 -0.28 (-5.19%) Closing price 04:00 PM EasternExtended Trading$5.12 0.00 (0.00%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.LENZ Therapeutics NASDAQ:LENZ$28.16 -0.57 (-1.98%) Closing price 04:00 PM EasternExtended Trading$28.10 -0.06 (-0.21%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Could Rally as EU Antitrust Case Nears Resolution Canada Goose Soars 30%—Is This Rally Built to Last? Palo Alto Networks: Buy The Dip, Long-Term Tailwinds Ahead Lowe’s Stock Uptrend Can Continue for These 2 Reasons CrowdStrike Near Breakout: Is Now the Time to Buy? Intel Refocuses: NEX Sale and Foundry Pivot Signal New Era Rivian Stock Below $20: Charging Up or in the Breakdown Lane? 3 Reasons Salesforce Could Be Back at All-Time Highs by June Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
